Post-earnings recap
Reported
Tue, Aug 11, 2026
EPS actual
$-2.85
EPS est.
$-0.57
EPS surprise
-400.00%
1-day move
-0.18%
Mineralys Therapeutics reported a significant loss in EPS, which contributed to a slight decline in stock price by 0.18%. The company has substantial cash reserves to support operations through 2028, but rising R&D expenses due to a royalty repurchase agreement raised concerns. The upcoming PDUFA date for lorundrostat could be a pivotal moment for the company, depending on the outcome.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.85 | N/A | -400.00% |
| Cash | $661.4M | N/A | N/A |
| R&D Expenses | $221.4M | N/A | N/A |
Management remains optimistic about the potential commercial launch of lorundrostat, with a PDUFA date set for December 22, 2026. They emphasized their strategic initiatives to differentiate the product in the market.
Management expressed confidence in maximizing lorundrostat's value.
They highlighted the significant efficacy of lorundrostat in chronic kidney disease patients.
Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious health conditions. Operating within the health care sector, its work is crucial as it aims to address unmet medical needs, particularly in the treatment of chronic diseases.
Last quarter
In Q1-2026, Mineralys reported an EPS of $-0.47, which was better than the expected $-0.51, resulting in a positive stock reaction of 2.87% the following day. However, revenue figures were not disclosed.
EPS beat streak
0Q
EPS beat rate
75%
Avg EPS surprise
-41.45%
Avg 1-day reaction
+4.68%
Investors are looking for signs of continued improvement in EPS and any potential revenue growth. The market is particularly focused on how the company is progressing with its product pipeline.
Bull case
If Mineralys can continue to beat EPS estimates and provide updates on successful trials or product launches, it could lead to a significant increase in stock value.
Bear case
Conversely, if the company fails to meet EPS expectations or provides no clear guidance on revenue growth, it could lead to a decline in investor confidence and stock price.
Key metrics to watch
Earnings Per Share (EPS)
$-0.51EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AWhile specific revenue estimates are not available, any growth in revenue would signal the company's ability to expand its market presence.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
The EPS figure will be critical in determining if the company continues its trend of beating estimates, which could influence investor sentiment.
Q2
Is there any update on the product pipeline or revenue growth?
Investors will be keen to understand the company's progress in its development efforts, as this could impact future revenue potential.
—
Est. EPS
$0.20
Est. Rev
$609M
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the potential for Mineralys to exceed EPS expectations again, given its recent track record of surprises.
Supporting evidence
Mineralys has beaten EPS estimates in 75% of the last eight quarters, indicating a strong operational trend.
The options market is pricing in a larger move than historical averages, suggesting that investors expect significant news.
The company's focus on innovative therapies may lead to unexpected positive developments that are not currently factored into consensus.
Key risk
If the EPS comes in below $-0.60, it could undermine the positive narrative built around the company's growth.
Pre-commit to what would confirm each case.
The market is debating whether Mineralys can maintain its positive earnings surprises and how it is progressing with its drug development.
Bull confirmed if
An EPS of $-0.50 or better would confirm the bullish sentiment and indicate continued operational improvement.
Bear confirmed if
An EPS worse than $-0.60 would reinforce concerns about the company's profitability and growth prospects.
What the market is pricing for the move.
Implied Move
±28.09%
Historical Avg
±5.6%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±28.1% while MLYS has averaged ±5.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
60.3%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.9M
75,000 sh
1 insider
Net
$1.9M
Net selling
Most Active Insiders· 1 open-market trade
$1.9M
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Mineralys beats expectations, history suggests the stock could rise by about 5.22%, confirming the positive trend.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
If the company misses EPS estimates, history indicates a potential decline of around 5.29%, which could shake investor confidence.
The lines on the call that would change the story.
Recent Transactions
Sep 30, 2026 · @ $25.46
75,000 sh
$1.9M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.